The Effect of Apalutamide on Thyroid Function in Prostate Cancer Patients.

Clare MoffattMelissa G LechnerTrevor E AngellJohn ShenAlexandra DrakakiGonzalo J AcostaTom Z LiangKaren Tsai

Published in: Journal of the Endocrine Society (2024)

APT-associated thyroid dysfunction presents as new or worsening hypothyroidism and should prompt initiation or increase in thyroid hormone replacement. Monitoring of thyroid function tests is recommended every 1 to 2 months for all patients on APT and 2 to 3 months after completion of APT.

Keyphrases

end stage renal disease
prostate cancer
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
oxidative stress
patient reported outcomes
replacement therapy
patient reported